作者: Kowa Chen , Aleksandra Gentry-Maharaj , Matthew Burnell , Catharina Steentoft , Lara Marcos-Silva
DOI: 10.1021/PR3010474
关键词:
摘要: The CA125 biomarker assay plays an important role in the diagnosis and management of primary invasive epithelial ovarian/tubal cancer (iEOC). However, a fundamental problem with is that it not cancer-specific may be elevated benign gynecological conditions such as ovarian neoplasms endometriosis. Aberrant O-glycosylation inherent specific property cells could potentially aid differentiating from these conditions, thereby improving specificity assay. We report on development novel microarray-based platform for profiling aberrant glycoforms, Neu5Acα2,6GalNAc (STn) GalNAc (Tn), present (MUC16) CA15-3 (MUC1). In blinded cohort study patients levels (30-500 kU/L) pelvic mass UK Ovarian Cancer Population Study (UKOPS), we measured STn-CA125, ST-CA125 STn-CA15-3. combined glycoform profile was able to distinguish ovarian/tubule (iEOCs) 61.1% at 90% sensitivity. findings suggest microarray glycoprofiling improve differential significantly reduce number elected further testing. approach warrants investigation other cancers.